Veterinary Medicine

hyd-vet-man-dog-right.jpg

 

On decreasing the concentration of deuterium below normal physiological level, the resulting depletion delayed the progression of several types of cancer in mice and prolonged the animals' survival. These findings were confirmed when dogs and cats with different spontaneous tumors were consuming DDW as drinking water. These experiments revealed that the tumors cannot tolerate the decrease of D concentration and after a relatively short time period (few weeks or months) they regress and then disappear. The first deuterium depleted drug, Vetera-DDW-25® A.U.V, was registered for the supportive therapy of tumorous dogs and cats in 1999.

 

Among pets (mostly dogs and cats) the average tumor rate is 3-4%. VETERA-DDW-25® is applicable orally (by drinking), its main indication is pre- and post-treatment of surgical interventions, or single treatment in case of non-operable tumors. VETERA-DDW-25® is special in regard to its high efficacy in several different tumor types, which is coupled with lack of side effects and the scantiness of in-home chemotherapeutical treatments on the market.

 

Mammary tumors in dogs and cats showed a response rate over 70%; with more than 50% of the animals achieving complete recovery. Similar efficacy was observed in dogs and cats bearing rectal tumors. More than 70% of cats with lymphoid leucosis achieved complete response. Sarcomatoid tumors in dogs showed a short-term response or no response at all.

 

In order to increase the effectiveness of deuterium depletion, an injectable formulation of DDW was developed to ensure a rapid decrease in D concentration especially in certain types of cancer, such as ulcerative, extensive, relapsed, metastasizing tumors, malignant melanoma, and sarcomatoid tumors which were fairly resistant to per os DDW treatment.

 

Local treatment induced regression of tumors that were resistant to previous oral DDW administration and produced advantageous conditions for subsequent surgical interventions. Microscopic evaluations of the tumors verified that DDW injection induced disappearance of tumor cell infiltration, demarcation and consequent rejection of invasive tumors; but was harmless to the healthy tissues in the environment of the tumor. Simultaneous oral and local treatment was initiated in some animals to enhance therapeutic effectiveness and to prevent relapses. As a result of the combined treatment, dogs became tumor-free and asymptomatic. DDW injection alone or in combination with surgery offers an effective cancer treatment of aggressive tumors with poor prognosis.